PS:
The previous adverse effects for PF-06939926 was in the P3 for 'ambulant' boys this year.
"The company reported instances of muscle weakness including inflammation of the heart tissue called myocarditis."
"Pfizer revealed that a data readout for the therapy expected next year has been postponed until the first quarter of 2023 in a November update."
No way, data read out more like 2024....IF the FDA let's them resume the program.
Is this ANP's Steven Bradbury moment?
Dr G and Diamond should do everything possible to bring forward the EMEA study.
.
UPDATE ON PFIZER’S PHASE 1B OPEN-LABEL MINI-DYSTROPHIN GENE THERAPY TRIAL FOR DUCHENNE, page-7
-
- There are more pages in this discussion • 71 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
